Peripheral blood leukocyte signatures as biomarkers in relapsed ovarian cancer patients receiving combined anti‐CD73/anti‐PD‐L1 immunotherapy in arm A of the NSGO‐OV‐UMB1/ENGOT‐OV30 trial

Peripheral blood leukocyte signatures as biomarkers in relapsed ovarian cancer patients receiving combined anti‐CD73/anti‐PD‐L1 immunotherapy in arm A of the NSGO‐OV‐UMB1/ENGOT‐OV30 trial

Immune checkpoint inhibitors have demonstrated limited efficacy in overcoming immunosuppression in patients with epithelial ovarian cancer (EOC). Although certain patients experience long‐term treatment benefit, reliable biomarkers for responder pre‐selection and the distinction of dominant immunosu...

Full description

Saved in:
Bibliographic Details
Main Authors: Luka Tandaric, Annika Auranen, Katrin Kleinmanns, René DePont Christensen, Liv Cecilie Vestrheim Thomsen, Cara Ellen Wogsland, Emmet McCormack, Johanna Mäenpää, Kristine Madsen, Karen Stampe Petersson, Mansoor Raza Mirza, Line Bjørge
Format: Article
Language:English
Published: Wiley 2025-05-01
Series:Molecular Oncology
Subjects:
biomarkers
durvalumab
immunotherapy
liquid biopsy
oleclumab
ovarian cancer
Online Access:https://doi.org/10.1002/1878-0261.13811
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1002/1878-0261.13811

Similar Items